Table 1.
Baseline demographic characteristics of the three study groups.
| Group 1 Full-dose mRNA-1273 (n = 100) | Group 2 Half-dose mRNA-1273 (n = 98) | Group 3 Full-dose BNT-162b2 (n = 100) | P values | |
|---|---|---|---|---|
| Age (Mean ± SD) | 39.85 ± 9.68 | 37.24 ± 12.43 | 38.98 ± 10.78 | 0.240 |
| Male, n (%) | 35 (35.0%) | 33 (33.7%) | 24 (24.0%) | 0.185 |
| Underlying systemic diseases, n (%) | ||||
| DM under OHA | 2 (2.0%) | 1 (1.0%) | 2 (2.0%) | 0.826 |
| DM under insulin | 1 (1.0%) | 0 (0.0%) | 0 (0.0%) | 0.370 |
| Hypertension | 5 (5.0%) | 6 (6.1%) | 7 (7.0%) | 0.838 |
| Coronary arterial disease | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | – |
| Congestive heart failure | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | – |
| Stroke | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | – |
| Chronic lung disease | 0 (0.0%) | 1 (1.0%) | 0 (0.0%) | 0.359 |
| Chronic viral hepatitis | 3 (3.0%) | 0 (0.0%) | 3 (3.0%) | 0.223 |
| Decompensated hepatic insufficiency | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | – |
| Chronic kidney disease | 2 (2.0%) | 0 (0.0%) | 1 (1.0%) | 0.370 |
| ESRD under dialysis | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | – |
| Hyperthyroidism | 3 (3.0%) | 1 (1.0%) | 1 (1.0%) | 0.450 |
| Hypothyroidism | 0 (0.0%) | 1 (1.0%) | 0 (0.0%) | 0.359 |
| Rheumatoid arthritis | 1 (1.0%) | 0 (0.0%) | 1 (1.0%) | 0.611 |
| Ankylosing spondylitis | 2 (2.0%) | 0 (0.0%) | 0 (0.0%) | 0.136 |
| Antiphospholipid syndrome | 2 (2.0%) | 1 (1.0%) | 0 (0.0%) | 0.367 |
| Systemic lupus erythematosus | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | – |
| Sjogren Syndrome | 1 (1.0%) | 0 (0.0%) | 1 (1.0%) | 0.611 |
| Malignancies | 0 (0.0%) | 3 (3.1%) | 1 (1.0%) | 0.162 |
| Seronegative spondyloarthritis | 0 (0.0%) | 1 (1.0%) | 2 (2.0%) | 0.367 |
| Autoimmune thyroiditis | 4 (4.0%) | 1 (1.0%) | 0 (0.0%) | 0.073 |
| Current medication, n (%) | ||||
| Methotrexate | 0 (0.0%) | 1 (1.0%) | 1 (1.0%) | 0.601 |
| Plaquenil | 2 (2.0%) | 2 (2.0%) | 3 (3.0%) | 0.870 |
| Rituximab | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | – |
| NSAID except COX-2 | 0 (0.0%) | 2 (2.0%) | 2 (2.0%) | 0.359 |
| COX-2 inhibitor | 3 (3.0%) | 3 (3.1%) | 3 (3.0%) | 1.000 |
| Sulfasalazine | 2 (2.0%) | 0 (0.0%) | 1 (1.0%) | 0.370 |
| Steroid | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | – |
| OPD visit for adverse effect | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | – |
Abbreviation: SD, standard deviation; DM, diabetes mellitus; OHA, oral hypoglycemic agent; ESRD, end stage renal disease; NSAID, non-steroidal anti-inflammatory drug; COX-2, cyclooxygenase-2; OPD, out-patient department.